用免疫检查点抑制剂治疗的高级非小细胞肺癌患者的长期存活率
1Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
Respiratory investigation
|November 20, 2023
概括
免疫检查点抑制剂 (ICI) 为没有驱动突变的高级非小细胞肺癌 (NSCLC) 患者提供了延长的生存期. 本综述总结了第一线ICI治疗的III期试验中的长期生存数据.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 肺部病理学 肺部病理学
背景情况:
- 肺癌是全球癌症死亡的主要原因,常常呈现转移.
- 缺乏可向突变的高级非小细胞肺癌 (NSCLC) 是一个治疗挑战.
- 针对PD-1/PD-L1和CTLA-4的免疫检查点抑制剂 (ICI) 在III期试验中显示出比标准治疗更高的疗效.
研究的目的:
- 通过一线ICI治疗的没有驱动突变的晚期NSCLC患者的长期生存数据进行审查和总结.
- 巩固关于ICI治疗对该患者群体的耐久性反应和长期影响的证据.
主要方法:
- 在没有可向基因组驱动突变的高级非小细胞肺癌 (NSCLC) 患者中评估一线免疫检查点抑制剂 (ICI) 的III期临床试验的系统审查.
- 从选定的试验中分析报告的长期生存结果和反应的持续时间.
主要成果:
- 包括PD-1或PD-L1抑制剂在内的一线ICI疗法在没有驱动突变的晚期NSCLC患者中显示出前所未有的延长存活率.
- 已经观察到长期的治疗效应,即使在停止ICI治疗后,益处也会持续下去.
- 大多数患有晚期NSCLC且无驱动突变的患者现在在第一线设置中接受ICI治疗,以实现长期反应.
结论:
- 第一线免疫检查点抑制剂在没有驱动突变的先进NSCLC的管理方面取得了重大进展,提供了持久的长期生存.
- 审查强调了对长期结果的综合数据的关键需求,以指导这种患者群体的最佳治疗策略.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.6K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
01:27Tumor Immunotherapy
530
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
530
01:21Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356